The Motley Fool
12 Jul 2026, 21:38 UTC · 11w ago
Verdict
Headline takes no side. We score ADPT +0.60 across four claims — strongly bullish.
+0.60strongly bullish
More positive than 77% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Adaptive Biotechnologies raised its full-year MRD guidance to between $260 million and $270 million.
More positive than 93% of claims this week
The company's first-quarter revenue increased by 35% to $70.9 million, with clonoSEQ test volume rising 41%.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 87% of claims this week
Adaptive Biotechnologies' net loss narrowed to $20 million in the first quarter from a trailing twelve-month loss of $49.7 million.
More positive than 79% of claims this week
Chief Scientific Officer Harlan Robins sold 386,240 shares at $22.01 per share under a preset trading plan.
More negative than 68% of claims this week
Which stocks this story touches
More positive than 77% of ticker scores this week
The company shows strong revenue growth, narrowing losses, and raised guidance, which outweighs the impact of an insider's pre-planned stock sale.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
1h ago
+35.4%
Price agrees with the score
$28.51 vs $21.06 close before publication (Jul 10) · not market-adjusted
ADPT chart →
